Portal for patients

​Actavis Announced Buying The Latest Developer Of Antibiotics

Actavis reached an agreement to acquire company Durata Therapeutics, a Chicago-based producer of antibacterial drugs. The transaction value is estimated at 675 million dollars.

Actavis Announced Buying The Latest Developer Of Antibiotics

According to the agreement, the owners of Durata securities will receive $23 per share, which is 66% more than shares costed at the closing of the exchange on Friday.

Actavis announced that after purchasing Durata European drugmaker will acquire the rights to dalbavancin, the latest antibiotic, registered in the United States this May. Acute bacterial infection of skin and soft tissues caused by Gram-positive organisms, including methicillin-resistant strains of S.aureus (MRSA) is treated by the new antibiotic.

Studies have shown that making two intravenous injections of dalbavancin, a second generation semisynthetic lipoglikopeptid, in the first day and on the eighth day is as effective as the use of linezolid twice a day for 14 days.

See also:

No comments

Application for treatment
MTEC 2019 (eng.-com)